1. Scrip
  2. >>Business
  3. >>Legal & IP

Big Pharmas Trust To The Science In Zantac Lawsuits

GSK And Sanofi Mount Vigorous Defence

 
• By Kevin Grogan

Billions of dollars have been wiped off the value of big pharma stocks as the market finally woke up to widescale litigation concerning allegations of increased cancer risk associated with the use of ranitidine. Two companies, GSK and Sanofi, are confident that there is no link. 

new gsk logo and hq
GSK Backs 'overwhelming weight of the scientific evidence' behind Zantac • Source: GSK

GSK plc has come out fighting after investors suddenly got nervous about ongoing litigation in the US over the heartburn drug Zantac, sending the UK major's share price down to its lowest level since 2008.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Deal Watch: FTC Keeps Current Merger Guidelines In Place, For Now

 
• By Joseph Haas

Plus deals involving Incyte/Genesis, Merck & Co./Epitopea, Merck Serono/Asceneuron, Tivic Health/Statera and more.

India Digital Personal Data Protection Norms: What It May Mean For Clinical Trials, Big Pharma GCCs

 
• By Anju Ghangurde

Legal heavyweights from Nishith Desai Associates, Anand and Anand, Corporate Law Group and EY partner and national cyber leader outline key compliance aspects that pharma and their global capability centers may need to factor as India moves to strengthen the framework for the protection of digital personal data.

Semaglutide In 2027 Medicare Price Negotiations; Most Other Drugs Lose Exclusivity By Then

 
• By Mandy Jackson

Novo took the biggest stock price hit of all the drug makers with products subject to Medicare price negotiations in 2027 under the IRA, but at least 11 of its peers on the list will be subject to generic competition between 2025 and 2027.

Lens On Pharma Marketing ‘Ploys’ In India: Can The Genie Be Tamed?

 
• By Anju Ghangurde

India cracks down on unethical marketing practices, with AbbVie in the eye of a storm for allegedly violating norms. While the action sends the right signal, a wider clean up including in the devices segment, where things may be “more harmful” may not be easy, say some experts.

More from Business